SCHEMBL17556326

SCHEMBL17556326

COc1cc(F)cc(-c2cccc(N)c2N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.44
▸ ABCB1 P08183 3/20 0.44
▸ BCR P11274 3/20 0.44
▸ CYP3A4 P08684 2/20 0.41
▸ CYP1A1 P04798 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2E1 P05181 1/20 0.41
▸ CYP2C8 P10632 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2A6 P11509 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP4B1 P13584 1/20 0.41
▸ CYP2B6 P20813 1/20 0.41
▸ CYP3A5 P20815 1/20 0.41
▸ CYP2A7 P20853 1/20 0.41
▸ CYP3A7 P24462 1/20 0.41
▸ CYP2F1 P24903 1/20 0.41
▸ CYP2C18 P33260 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ CYP2J2 P51589 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17573181 0.86 ABL1 (0.42) ABL1ABCB1BCRCYP3A4CYP1A1
SCHEMBL28460183 0.83 TAAR1 (0.39) CYP3A4ALDH1A1MAPTPIK3CDBRD4
SCHEMBL29414649 0.83 TAAR1 (0.39) CYP3A4ALDH1A1MAPTPIK3CDBRD4
SCHEMBL3490386 0.80 TDO2 (0.54) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL17556370 0.79 CHRNB2 (0.43) ALDH1A1MAPT
SCHEMBL18480719 0.79 CD44 (0.39) ABL1CYP3A4LRRK2ALDH1A1FYN
SCHEMBL17555449 0.77 CYP1A1 (0.42) CYP3A4CYP1A1CYP1A2CYP2D6CYP2C9
SCHEMBL3491387 0.76 ABL1 (0.52) ABL1ABCB1BCRCYP3A4ALDH1A1
SCHEMBL17555617 0.76 FYN (0.44) CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8
SCHEMBL17556255 0.76 PIK3CD (0.49) ABL1ABCB1BCRLRRK2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-08-27 — — US disclosed
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-08-27 — — US disclosed
US-20190119276-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC 2019-04-25 — — US disclosed
US-20190119276-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC 2019-04-25 — — US disclosed
US-10202377-B2 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-12 — — US disclosed
US-10202377-B2 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-12 — — US disclosed
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-03-29 — — US disclosed
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-03-29 — — US disclosed
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-03-29 — — US disclosed
US-9657016-B2 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-05-23 — — US disclosed
US-9657016-B2 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-05-23 — — US disclosed
US-9657016-B2 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2017-05-23 — — US disclosed
WO-2017023989-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC. (US) 2017-02-09 — — WO disclosed
WO-2017023989-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC. (US) 2017-02-09 — — WO disclosed
WO-2016040180-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO disclosed
US-20160068529-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2016-03-10 — — US disclosed
US-20160068529-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2016-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068529-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A ABL1 1374/4885ABCB1 1698/4885BCR 2135/4885
US-10392383-B2 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WNT1, WNT3, WNT3A ABL1 1330/4885ABCB1 1537/4885BCR 2076/4885
US-20180086754-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A ABL1 1374/4885ABCB1 1698/4885BCR 2135/4885
US-10202377-B2 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A ABL1 1374/4885ABCB1 1698/4885BCR 2135/4885
US-20190119276-A1 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A ABL1 1374/4885ABCB1 1698/4885BCR 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback